Cetek Corporation has announced a screening agreement with Taisho Pharmaceutical Co., Ltd. utilizing Cetek’s proprietary technology in screening Taisho’s targets.
Under the agreement, Cetek will develop assays for Taisho’s targets and screen against libraries from Taisho.
“We are pleased to gain access to Cetek’s screening technology and have it contribute to our drug discovery efforts,” said Dr. Shigeo Morimoto, Head of Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd. “Taisho is our first Japanese client and will join our growing list of North American and European clients. We look forward to helping Taisho accelerate several of their important research projects”, said James L. Waters, President of Cetek.
Cetek Corporation, has developed a screening technology based on capillary electrophoresis (CE) that can rapidly develop targets into a high-throughput screening assay.
The Cetek CE Assay can quickly discover valuable ‘hits’ in synthetic libraries, combinatorial mixtures, and natural product extracts.
The technology was originally developed at the Barnett Institute of Northeastern University and is licensed exclusively to Cetek.
This proprietary technology combines laser- induced fluorescence or UV detection with high resolution CE. Cetek focuses on collaborating with leading pharmaceutical and biotechnology companies to derive benefits from this powerful screening technology.
The company is a privately held drug discovery company with laboratories located in Marlborough, MA.